1. 105999245 含乌司他丁的药物组合物在制备治疗胆囊癌药物中的用途
CN
12.10.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
102016000562453
广东天普生化医药股份有限公司
孙明晖
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了含乌司他丁的药物组合物在制备治疗胆囊癌药物中的用途。本发明药物组合物包括乌司他丁和β‑七叶皂甙钠。经动物试验证实，该组合物对人胆囊癌裸鼠移植瘤有较明显的抑制作用，且其毒副作用低，安全性高，可以作为治疗胆囊癌的药物使用。
2. 105854008 含有乌司他丁的组合物在制备治疗口腔癌药物中的用途
CN
17.08.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610374710.X
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药领域，具体涉及含有乌司他丁的组合物在制备治疗口腔癌药物中的用途。本发明提供的含有乌司他丁的组合物在制备治疗口腔癌药物中的用途，经细胞体外试验发现，本发明提供的乌司他丁与三七总皂苷的组合物对体外口腔鳞状细胞癌细胞的生长具有显著的抑制作用。同时，本发明提供的含有乌司他丁组合物的注射液对采用DMBA诱发口腔癌的叙利亚金黄地鼠模型具有显著的治疗效果，乌司他丁与三七总皂苷的组合物可以显著降低口腔癌金黄地鼠口腔黏膜单纯增生、异常增生和癌的数目，更有利于口腔癌患者的康复。
3. 105833257 含有乌司他丁的组合物在制备治疗脂肪肝药物中的用途
CN
10.08.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
102016000374778
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，公开了含有乌司他丁的组合物在制备治疗脂肪肝药物中的用途，所述组合物包括乌司他丁和山莨菪碱。经动物试验证实，该组合物对大鼠酒精性脂肪肝有很好的治疗效果，可作为治疗脂肪肝的药物使用。
4. 105837685 一种基于阴离子交换树脂纯化乌司他丁的方法
CN
10.08.2016
C07K 14/81 Loading...
C07K 14/81
Loading...
102016000323339
广东天普生化医药股份有限公司
王旭
C07K 14/81
Loading...
本发明属于医药技术领域，具体涉及一种基于阴离子交换树脂纯化乌司他丁的方法。该方法先用壳聚糖和甲壳素的混合物吸附分离得到乌司他丁粗品，然后将粗品与海藻酸盐混合后依次进行超滤、阴离子交接树脂纯化、超滤，最后将超滤后得到的截留液冷冻干燥，得到乌司他丁纯品。由本申请提供的基于阴离子交换树脂纯化乌司他丁的方法，缩短了纯化工艺，乌司他丁的收率和纯度高，其中，乌司他丁的收率达到87％；比活力达到4900IU/mg蛋白。
5. 105816862 乌司他丁在制备治疗前列腺癌药物中的用途
CN
03.08.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
102016000153816
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了乌司他丁在制备治疗前列腺癌药物中的用途。本发明证明使用乌司他丁治疗前列腺癌裸鼠，能显著缓解前列腺癌裸鼠的体重减轻和抑制肿瘤体积的增长；此外，本发明所述的乌司他丁还通过增加前列腺癌裸鼠TNF?α的表达，促进肿瘤细胞凋亡，降低NF?kB表达，减少相关炎症因子的产生，最终达到抗前列腺癌的目的。本发明所述的乌司他丁不良反应少，毒副作用低，安全性高，且成本低廉，对治疗前列腺癌具有较好的疗效。
6. 105797143 含有乌司他丁的组合物在制备治疗膀胱癌药物中的用途
CN
27.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610374777.3
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了含有乌司他丁的组合物在制备治疗膀胱癌药物中的用途，该组合物包括乌司他丁和生长抑素，经动物试验证实，该组合物对人膀胱癌裸鼠移植瘤有明显的抑制作用，且其毒副作用低，可以作为治疗膀胱癌的药物使用。
7. 105797144 含有乌司他丁的组合物在制备治疗前列腺炎药物中的用途
CN
27.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610374816.X
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药领域，具体涉及含有乌司他丁的组合物在制备治疗慢性前列腺炎药物中的用途。本发明提供的含有乌司他丁的组合物在制备治疗慢性前列腺炎药物中的用途，所述组合物包括乌司他丁和紫杉醇。经试验发现，乌司他丁与紫杉醇的组合物可以显著的降低慢性前列腺炎大鼠的前列腺湿重、体积以及前列腺指数，说明本发明提供的含有乌司他丁的组合物对慢性前列腺炎具有显著的治疗效果。而且，经前列腺组织病理学检查发现，乌司他丁与紫杉醇的组合物可以显著改善慢性前列腺炎的组织病变，更有利于慢性前列腺炎患者的恢复。
8. 105770875 乌司他丁在制备治疗食管癌药物中的用途
CN
20.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
102016000153943
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了乌司他丁在制备治疗食管癌药物中的用途。本发明证明，使用乌司他丁治疗食管癌裸鼠，能显著缓解食管癌裸鼠的体重减轻和抑制肿瘤体积的增长，并能显著减轻食管癌肿瘤重量，具有较高的抑瘤率。此外，乌司他丁通过增加食管癌裸鼠肿瘤组织中促凋亡蛋白Bax和细胞凋亡终末剪切酶caspase?3的表达，降低抑凋亡蛋白Bcl?2的表达，促进肿瘤细胞凋亡，最终达到抗食管癌的目的。本发明所述的乌司他丁不良反应少，毒副作用低，安全性高，且成本低廉，对治疗食管癌具有较好的疗效。
9. 105770874 乌司他丁在制备治疗多发性硬化药物中的用途
CN
20.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
102016000153866
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了乌司他丁在制备治疗多发性硬化药物中的用途。本发明证实，使用乌司他丁治疗多发性硬化大鼠(EAE模型)，能显著缓解EAE大鼠的体重减轻，显著降低EAE大鼠死亡率和延长发病潜伏时间，并具有神经保护作用；此外，乌司他丁还通过降低IL?2、IFN?γ、TNF?α的表达，增加TGF?β和IL?10的表达，恢复Th1/Th2细胞因子的平衡，缓解EAE病程，并通过调节促凋亡Bax、Fas蛋白和抑制凋亡Bcl蛋白的表达，促进EAE的恢复。本发明乌司他丁的毒副作用低，安全性高，对心、肝、肾、肺均具有保护作用，且成本低廉，作为治疗多发性硬化药物具有很好的开发前景。
10. 105770877 乌司他丁在制备治疗膀胱癌药物中的用途
CN
20.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610374776.9
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了乌司他丁在制备治疗膀胱癌药物中的用途。经动物试验证实，乌司他丁对人膀胱癌裸鼠移植瘤有明显的抑制作用，且其毒副作用低，可以作为治疗膀胱癌的药物使用。
11. 105770876 乌司他丁在制备治疗慢性前列腺炎药物中的用途
CN
20.07.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610374709.7
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药领域，具体涉及乌司他丁在制备治疗慢性前列腺炎药物中的用途。本发明提供的乌司他丁在制备治疗慢性前列腺炎药物中的用途，经试验发现，乌司他丁注射液可以显著的降低慢性前列腺炎大鼠的前列腺湿重、体积以及前列腺指数，其中高剂量组的效果最好，说明本发明提供的乌司他丁对慢性前列腺炎具有显著的治疗效果。而且，经前列腺组织病理学检查发现，乌司他丁可以显著改善慢性前列腺炎的组织病变，更有利于慢性前列腺炎患者的恢复。
12. 105753975 一种基于疏水柱的乌司他丁纯化方法
CN
13.07.2016
C07K 14/81 Loading...
C07K 14/81
Loading...
102016000280471
广东天普生化医药股份有限公司
王旭
C07K 14/81
Loading...
本发明属于医药技术领域，具体涉及一种基于疏水柱的乌司他丁纯化方法。具体来说，首先对乌司他丁粗品进行沉淀、过滤、调pH等前处理，通过疏水柱层析对乌司他丁进行分离纯化，除掉杂蛋白和有色基团，特别是有效的减少了乌司他丁中人尿激肽原酶的含量；本发明可将总收率提高至75％以上，产品比活达到4000U/mg·pr。
13. 105753974 一种基于亲和层析柱的乌司他丁纯化方法
CN
13.07.2016
C07K 14/81 Loading...
C07K 14/81
Loading...
102016000280456
广东天普生化医药股份有限公司
王旭
C07K 14/81
Loading...
本发明涉及一种基于亲和层析柱的乌司他丁纯化方法，该方法包括以下步骤：尿液处理、疏水柱层析、亲和层析、凝胶过滤层析、洗涤、冻干，最后所得到的乌司他丁经过纯化试验发现乌司他丁的总收率提高到85％以上，总效价在6500iu/mg以上，采用了层析柱纯化处理，操作简单，且优选的填料和流速等参数提高了生产效率，大大降低生产成本，具有进一步开发利用的价值。
14. 105754977 一种制备人尿激肽原酶粗制品的方法
CN
13.07.2016
C12N 9/64 Loading...
C12N 9/64
Loading...
201610205115.3
广东天普生化医药股份有限公司
王旭
C12N 9/64
Loading...
本发明涉及一种尿蛋白的提取方法，尤其涉及一种制备人尿激肽原酶粗制品的方法。本发明提供的制备人尿激肽原酶粗制品的方法是采用阴离子交换树脂作为吸附剂吸附尿液中的尿蛋白，然后收集吸附尿蛋白的树脂，集中洗脱，接着将洗脱液通过阳离子交换树脂吸附人尿激肽原酶，从而实现人尿激肽原酶和人尿胰蛋白酶抑制剂的分离。本发明提供的制备人尿激肽原酶粗制品的方法可以有效的分离人尿激肽原酶和人尿胰蛋白酶抑制剂，便于人尿激肽原酶和人尿胰蛋白酶抑制剂后续的纯化处理，提高纯化率，而且该方法实现了两种蛋白粗制品的联产，可以大大的降低生产成本。
15. 105753976 一种基于阳离子交换树脂纯化乌司他丁的方法
CN
13.07.2016
C07K 14/81 Loading...
C07K 14/81
Loading...
102016000323431
广东天普生化医药股份有限公司
王旭
C07K 14/81
Loading...
本申请属于医药技术领域，具体涉及一种基于阳离子交换树脂纯化乌司他丁的方法。该方法将壳聚糖和海藻酸盐与初步过滤后的尿液混合后超滤，再将超滤得到的截留液依次用阳离子交换树脂、超滤纯化。由本申请提供的基于阳离子交换树脂纯化乌司他丁的方法，缩短了纯化工艺，乌司他丁的收率和纯度高，其中，乌司他丁的收率达到75％以上；比活力达到4750IU/mg蛋白。
16. 105753977 一种规模化生产高纯度乌司他丁的方法
CN
13.07.2016
C07K 14/81 Loading...
C07K 14/81
Loading...
102016000323432
广东天普生化医药股份有限公司
王旭
C07K 14/81
Loading...
本发明属于医药技术领域，具体涉及一种规模化生产高纯度乌司他丁的方法。该方法将壳聚糖与海藻酸盐与初步过滤后的尿液混合，然后采用超滤与乙醇分级沉淀联用的方式进行纯化。本申请提供的规模化生产高纯度乌司他丁的方法，操作方便，可控性强，纯化工艺简单，适于大规模生产，而且，乌司他丁的收率高达72％，纯化得到的蛋白分子量为67000±200D，抑制胰蛋白酶的活性高于4780IU/mg蛋白。
17. 105597091 乌司他丁在制备治疗放/化疗引起的皮肤损伤药物中的用途
CN
25.05.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610100426.3
广东天普生化医药股份有限公司
宋建东
A61K 38/57
Loading...
本发明属于医药技术领域，具体公开了乌司他丁在制备治疗放/化疗引起的皮肤损伤药物中的用途。经动物试验证实，乌司他丁对放/化疗引起的皮肤损伤有明显的保护作用，且其毒副作用低，可以作为治疗放/化疗引起的皮肤损伤的药物使用。
18. 105597084 乌司他丁在制备防治放/化疗引起的粘膜损伤药物中的用途
CN
25.05.2016
A61K 38/17 Loading...
A61K 38/17
Loading...
201610102646.X
广东天普生化医药股份有限公司
宋建东
A61K 38/17
Loading...
本发明属于医药领域，具体涉及乌司他丁在制备防治放/化疗引起的粘膜损伤药物中的用途。本发明提供的乌司他丁在制备防治放/化疗引起的粘膜损伤药物中的用途，经试验证明乌司他丁对化疗常用药物MTX引起的口腔粘膜损伤及放疗引起的急性放射性粘膜炎均具有显著的防治效果。
19. 105596302 一种乌司他丁冻干粉制剂及其制备方法
CN
25.05.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
201610069989.0
广东天普生化医药股份有限公司
王旭
A61K 9/19
Loading...
本发明涉及一种乌司他丁冻干粉制剂及其制备方法。所述乌司他丁冻干粉制剂的配方为，每1000支：乌司他丁2500万单位～10000万单位、甘露醇1～30g、氯化钠0～10g、磷酸氢二钠0～5g和磷酸二氢钠0～5g。本发明提供的乌司他丁冻干粉制剂的制备方法有以下特点：将乌司他丁与辅料分开溶解，对活性成分乌司他丁现配现用；在2～4℃的低温环境下配制冻干前药液，并在整个配置过程中保持这一温度范围，保证乌司他丁的稳定性；在冷冻干燥的预冻过程中采用“快‑慢‑快”的三步预冻方式，加快了其干燥速率，同时提高了其复溶性能。按照本发明提供配方与制备方法制成的乌司他丁冻干粉制剂复溶性能与稳定性均较为优异。
20. 105535951 一种乌司他丁注射液及其制备方法
CN
04.05.2016
A61K 38/57 Loading...
A61K 38/57
Loading...
201610069990.3
广东天普生化医药股份有限公司
王旭
A61K 38/57
Loading...
本发明涉及一种乌司他丁注射液及其制备方法。该乌司他丁注射液的配方为，每1000支：乌司他丁2500万单位～10000万单位、甘露醇1～30g、氯化钠0～10g、磷酸氢二钠0～5g、磷酸二氢钠0～5g和注射用水。本发明提供的乌司他丁注射液配制方法中，先配制2～4℃的辅料溶液，并使用添加量为1～5g、平均粒径为6～9µm的活性炭在2～4℃下对配置好的辅料溶液低温吸附处理12～20分钟后，再利用处理后的辅料溶液溶解乌司他丁。利用本发明提供的配方与制备方法配制的乌司他丁注射液，不良反应发生率相对较低、稳定性相对较高。
21. 105087531 一种制备尿激酶的方法
CN
25.11.2015
C12N 9/72 Loading...
C12N 9/72
Loading...
201510549397.4
广东天普生化医药股份有限公司
郑少亮
C12N 9/72
Loading...
本发明涉及一种直接在小便池或便斗中用装改性硅胶的滤布袋吸附尿液中的尿蛋白，并将吸附尿蛋白的滤布袋运至加工点进行后续处理的尿蛋白富集方法。本方法利用特定尿蛋白的等电点性质，通过使用包括改性硅胶,大孔树脂，甲壳素，离子树脂等；对尿胰蛋白酶抑制剂、人尿激肽原酶、尿激酶等尿蛋白直接有效吸附，避免了尿液的收集步骤。该方法对厕所的卫生状况无明显影响，并大幅度降低了尿液运输的成本以及带来的一系列环境问题。
22. 104940914 人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物
CN
30.09.2015
A61K 38/49 Loading...
A61K 38/49
Loading...
201510403851.5
广东天普生化医药股份有限公司
王旭
A61K 38/49
Loading...
本发明属于医药领域，具体涉及人尿激肽原酶的新用途及含有人尿激肽原酶的药物组合物。本发明提供的人尿激肽原酶在制备治疗老年痴呆症药物中的用途。本发明还提供了治疗老年痴呆症的药物组合物，该药物组合物包括人尿激肽原酶和银杏内酯，还包括己酮可可碱，所述药物组合物可以显著恢复老年痴呆症患者的记忆力能力和提高老年痴呆症患者的认知能力，延缓老年痴呆症的发病进程，大大改善老年痴呆症患者的生活质量，提高老年痴呆症患者治疗的顺应性，提高治疗效果，为老年痴呆症患者提供一种有效的治疗药物，大大的减轻老年痴呆症患者的痛苦。
23. 101972471 Application of Ulinastatin in preparing drug for curing autoimmune encephalomyelitis and pharmaceutical composition thereof
CN
16.02.2011
A61K 38/57 Loading...
A61K 38/57
Loading...
201010299506.9
Guangdong Techpool Bio-Pharma Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The invention relates to an application of Ulinastatin in preparing a drug for curing autoimmune encephalomyelitis, and the drug related by the invention is derived from natural protein drugs purified by human urine, has stable and reliable quality and less adverse effects, and overcomes the defects of more side effects, influenced life quality of patients even caused death and the like existing in the common drugs such as glucocorticoid and the like for curing autoimmune encephalomyelitis. Contrastive studies of curative effects on animal models of the autoimmune encephalomyelitis find that Ulinastatin has the same curative effect as hormone.
24. 101967468 Recombinant human kallidinogenase
CN
09.02.2011
C12N 9/48 Loading...
C12N 9/48
Loading...
201010198962.4
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
C12N 9/48
Loading...
The invention relates to human kallidinogenase and a production method thereof. The recombinant human kallidinogenase is produced by using molecular biological technology and host cells for expressing recombinant proteins and by purifying the recombinant proteins by using affinity chromatography. The recombinant human kallidinogenase has various applications in clinic, and the side effect of the recombinant human kallidinogenase is reduced obviously.
25. 101954071 Use of ulinastatin in preparation of medicament for treating systemic lupus erythematosus and medicinal composition of ulinastatin
CN
26.01.2011
A61K 38/57 Loading...
A61K 38/57
Loading...
201010299500.1
Guangdong Techpool Biochemical Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The invention relates to the use of ulinastatin in the preparation of a medicament for treating systemic lupus erythematosus. The medicament of the invention is derived from natural protein medicaments extracted from human urine, has a stable and reliable quality and fewer unwanted effects and overcomes the shortcomings of generating more side effects, influencing the living quality of a patient, even causing death of the patient and the like when the conventional medicaments such as glucocorticoid, yclophosphamide, azathioprine and cyclosporine A are used for treating the systemic lupus erythematosus. According to the comparative study on the treatment effect of lupous animal models, the treatment effect of the ulinastatin is the same as that of a hormone contrast group.
26. 101954072 Use of ulinastatin in preparation of drugs for treating rheumatoid arthritis and pharmaceutical composition thereof
CN
26.01.2011
A61K 38/57 Loading...
A61K 38/57
Loading...
201010299510.5
Guangdong Techpool Biochemical Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The invention relates to an application of ulinastatin in the preparation of drugs for treating rheumatoid arthritis. The related drugs are derived from natural proteins which are extracted from human urine, have stable and reliable quality and few adverse reactions and can overcome the shortcomings of more side effects and the like in the traditional drugs for treating the rheumatoid arthritis. The efficacy comparison studies of rheumatoid arthritis animal models prove that the efficacy of the ulinastatin is better than an amethopterin group, and the side effects are few.
27. 101897959 Recombinant human pancreatic kininogenase-containing medicine for treating and/or preventing cerebral infarction
CN
01.12.2010
A61K 38/48 Loading...
A61K 38/48
Loading...
201010193240.X
Techpool Bio-Pharma Co., Ltd.
Fu Heliang
A61K 38/48
Loading...
The invention relates to the use of recombinant human pancreatic kininogenase composite in the preparation of medicine for treating and/or preventing the cerebral infarction. Recombinant human pancreatic kininogenase is prepared by being combined with a host cell expressing the recombinant protein by means of molecular biology technology, thus having obvious treatment and/or prevention function(s) for the cerebral infarction. The recombinant human pancreatic kininogenase is generally used in a form of pharmaceutical composite such as freeze-dried powder injection or liquid injection.
28. 101879308 Application of human urinary kallidinogenase in preparing medicine for treating acute renal failureacute renal failure
CN
10.11.2010
A61K 38/48 Loading...
A61K 38/48
Loading...
201010200138.8
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/48
Loading...
The invention relates to a novel medicine application of human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating acute renal failureacute renal failure.
29. 101879310 Application of human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy
CN
10.11.2010
A61K 38/49 Loading...
A61K 38/49
Loading...
201010200140.5
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/49
Loading...
The invention relates to a novel medicine application of human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating diabetic nephropathy.
30. 101879309 Application of human urinary kallidinogenase in preparing medicine for treating diabetic foot ulcers
CN
10.11.2010
A61K 38/48 Loading...
A61K 38/48
Loading...
201010200141.X
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/48
Loading...
The invention relates to a novel medicine application of the human urinary kallidinogenase, i.e. the application of the human urinary kallidinogenase in preparing medicine for treating diabetic foot ulcers.
31. 101863974 Method for enriching urine protein directly
CN
20.10.2010
C07K 14/81 Loading...
C07K 14/81
Loading...
200910157899.7
Techpool Bio-Pharma Co., Ltd.
Fu Heliang
C07K 14/81
Loading...
The invention relates to a urine protein enriching method. In the method, urine protein in urine is absorbed directly by an adsorbent in a urinal or a pee hopper, and the adsorbent for adsorbing the urine protein is conveyed to a working point for follow-up treatment; and based on the isoelectric point properties of specific urine protein, the urine protein such as urinary trypsin inhibitor, human urinary kininogenase, urokinase and the like is adsorbed directly and effectively by using the specific adsorbent such as ion exchange resin, and thus, the step of collecting the urine is avoided. The method does not influence sanitation of toilets obviously, reduces the cost of urine transportation substantially and solves a series of environmental problems.
32. 101439181 Stable water injection medicament composition containing Ulinastatin
CN
27.05.2009
A61K 38/57 Loading...
A61K 38/57
Loading...
200810187703.4
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Lei Yao
A61K 38/57
Loading...
The invention discloses a stable ulinastatin pharmaceutical composition which contains an effective dose of ulinastatin and a pharmaceutical excipient with a certain proportion. Wherein, the excipient can be one or more of mannitol, sodium chloride, sodium acetate and acetic acid, and the range of pH value is 4.2-6.0. The composition is generally used in the form of injection, when in clinical application, the composition can be directly used for intravenous infusion and the composition can significantly improve the problem that the activity of an ulinastatin freeze-dried sterile injection powder preparation is easy to decrease during the preparation.
33. 101439180 Medicament composition for improving stability of Ulinastatin
CN
27.05.2009
A61K 38/57 Loading...
A61K 38/57
Loading...
200810187702.X
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Lei Yao
A61K 38/57
Loading...
The invention discloses a stable ulinastatin sterile injection powder pharmaceutical composition which contains an effective dose of ulinastatin and a pharmaceutical excipient, and the excipient is one or the combination of a plurality of kinds of mannitol, hydrolyzed gelatin, dextran and sodium chloride. The composition is generally used in the form of the freeze-dried sterile injection powder, when in clinical application, the composition is dissolved in glucose or physiological saline and other large infusions, and the composition can significantly reduce the decrease of the activity of the ulinastatin in water solution.
34. 101423541 Separation method of nucleic acid and glycosaminoglycan
CN
06.05.2009
C07H 21/00 Loading...
C07H 21/00
Loading...
200810187244.X
Guangdong Tianpu Biochemistry Medicine Co., Ltd.
Miao Piqu
C07H 21/00
Loading...
The invention relates to a simple and high-efficiency method for effectively separating nucleic acid from glycosaminoglycan in a mixture of nucleic acid and glycosaminoglycan through the difference in the solubility of nucleic acid, glycosaminoglycan and calcium salt thereof under different conditions.
35. 101301307 Use of DFT in preparing medicament for treating and preventing sepsis
CN
12.11.2008
A61K 31/711 Loading...
A61K 31/711
Loading...
200810126002.X
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 31/711
Loading...
The invention relates to an application of DTF (Defibrotide) in preparation of a drug for curing and preventing pyaemia and a drug composition prepared by the method. The drug composition of the invention has notable cure and prevention effects on pyaemia. The drug composition of the invention is usually used in the form of freeze-dried acanthopanax powder spasmolytic, injection or capsule.
36. 101301306 Use of DFT in preparing medicament for treating and preventing shock
CN
12.11.2008
A61K 31/711 Loading...
A61K 31/711
Loading...
200810126001.5
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 31/711
Loading...
The invention relates to an application of DTF (Defibrotide) in preparation of a drug for curing and preventing shock and a drug composition prepared by the method. The drug composition of the invention has notable cure and prevention effects on shock. The drug composition of the invention is usually used in the form of freeze-dried acanthopanax powder spasmolytic, injection or capsule.
37. 101301308 Use of DFT in preparing medicament for treating and preventing disseminated intravascular coagulation
CN
12.11.2008
A61K 31/711 Loading...
A61K 31/711
Loading...
200810126003.4
Guangdong Techpool Biological Pharmaceutical Co., Ltd.
Fu Heliang
A61K 31/711
Loading...
The invention relates to an application of DTF (Defibrotide) in preparation of a drug for curing and preventing disseminated intravascular coagulation (DIC) and drug composition prepared by the method. The drug composition of the invention has obvious cure and prevention effects on disseminated intravascular coagulation. The drug composition of the invention is usually used in the form of freeze-dried acanthopanax powder spasmolytic, injection or capsule.
38. WO/2008/124974 USE OF HUMAN URINARY KALLIDINOGENASE FOR MANUFACTURING A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF HYPERTENSION COMPLICATED BY CEREBRAL INFARCTION
WO
23.10.2008
A61K 38/49 Loading...
A61K 38/49
Loading...
PCT/CN2007/002096
TECHPOOL BIO-PHARMA CO., LTD.
FU, Heliang
A61K 38/49
Loading...
A use of human urinary kallidinogenase for manufacturing a medicament for the treatment and/or prevention of hypertension complicated by cerebral infarction is provided. A pharmaceutical composition comprising human urinary kallidinogenase and pharmaceutically acceptable adjuvants is also provided. Human urinary kallidinogenase is efficacious against hypertension complicated by cerebral infarction. The present medicament is a pharmaceutical composition containing an appropriate proportion of human urinary kallidinogenase and pharmaceutically acceptable adjuvants, wherein the dosage form includes freeze-dried powder or injection solution.
39. 101134106 Pharmaceutical composition containing human urine kininogenase for treating cerebral infarction
CN
05.03.2008
A61K 38/49 Loading...
A61K 38/49
Loading...
200710123537.7
Guangdong Tianpu Biology Chemical Medical Co., Ltd.
Fu Heliang
A61K 38/49
Loading...
The present invention relates to the application of human urokininogenase with single SDS-PAGE electrophoresis strip in serving as active component of medicine composition for treating acute cerebral infarction. The human urokininogenase with single SDS-PAGE electrophoresis strip separated from human urea for the first time has obvious effect of treating acute cerebral infarction. The human urokininogenase of the present invention is normally in the form of medicine composition, such as freeze dried powder for injection or liquid injection.
40. 101134105 Pharmaceutical composition containing recombination human pancreatic kininogenase for treating and/or preventing cerebral infarction
CN
05.03.2008
A61K 38/48 Loading...
A61K 38/48
Loading...
200710123538.1
Guangdong Tianpu Biology Chemical Medical Co., Ltd.
Fu Heliang
A61K 38/48
Loading...
The present invention relates to the use of recombinant human kallidinogenase composition in preparing medicine for preventing and treating cerebral infarction. The recombinant human kallidinogenase composition is prepared with recombinant human kallidinogenase through combination with the host cell expressing the recombinant protein by means of molecular biology technology. It has obvious effect of preventing and treating cerebral infarction. The recombinant human kallidinogenase composition of the present invention is normally in the form of medicine composition, such as freeze dried powder for injection or liquid injection.
41. 101134953 Recombinant human pancreas kininogenase
CN
05.03.2008
C12N 9/76 Loading...
C12N 9/76
Loading...
200710123540.9
Guangdong Tianpu Biology Chemical Medical Co., Ltd.
Fu Heliang
C12N 9/76
Loading...
The present invention relates to one kind of recombinant kallidinogenase and its preparation process. The recombinant kallidinogenase is produced by means of molecular biological technology and with host cell for expressing recombinant protein, and is purified through an affinity chromatographic process. It has several clinical uses and less side effects.
42. 101134952 Human urine kininogenase and method for making same
CN
05.03.2008
C12N 9/72 Loading...
C12N 9/72
Loading...
200710123539.6
Guangdong Tianpu Biology Chemical Medical Co., Ltd.
Fu Heliang
C12N 9/72
Loading...
The present invention relates to the research on the structural determination, enzymological property, etc of one kind of human urinary kininogenase and its preparation process. The human urinary kininogenase is separated from human urine. It has one single protein component and may be used as the active medicinal component in treating several diseases.
43. 101095948 Use of ulinastain in the preparing of treating and/or preventing sudden arrest of heart beat tritocerebrum damnification medicine
CN
02.01.2008
A61K 38/57 Loading...
A61K 38/57
Loading...
200710111222.0
Guangdong Techpool Bio-pharma Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The invention relates to the application of Urinary Trypsin Inhibitor (UTI)for preparing medicine that can prevent or treat brain damage after sudden arrest of heart beat. The effect is distinctive. The medicine is generally prepared into freeze dried or injection.
44. 101024075 Use of ulinastatin for preparing medicine for treating and protecting multi-organ function injury
CN
29.08.2007
A61K 38/57 Loading...
A61K 38/57
Loading...
200710086402.8
Guangdong Tianpu Biological-Chemical Medicine Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The present invention relates to an application of human urinary trypsin inhibitor for curing and/or protecting organ function injury and its medicine composition. Said medicine composition contains human urinary trypsin inhibitor and medicinal auxiliary material according to a certain ratio. Said medicine composition can be made into freeze-dried powder preparation or injection preparation.
45. 101024073 Use of humanbody kinino genase in preparing medicine for treating and preventing hypertension and cerebral infraction
CN
29.08.2007
A61K 38/43 Loading...
A61K 38/43
Loading...
200710090135.1
Tianpu Biological Pharmaceutical Co., Ltd., Guangdong
Fu Heliang
A61K 38/43
Loading...
The present invention relates to an application of human urinary kallidinogenase in preparation of medicine for curing and/or preventing hypertension complicated with cerebral infarction and its medicine composition. Said medicine composition includes human urinary kallidinogenase and medicinal auxiliary material according to a certain ratio. Said medicine composition can be made into freeze-dried powder preparation or injection preparation.
46. 101020049 Use of ulinastatin in preparing medicine for treating and/or preventing spinal cord injury
CN
22.08.2007
A61K 38/57 Loading...
A61K 38/57
Loading...
200710086674.8
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The present invention relates to the application of ulinastatin in preparing medicine for preventing and treating spinal cord injury. Ulinastatin has obvious spinal cord injury preventing and treating effect. The medicine is prepared into injection or freeze dried powder for injection.
47. 101020048 Pyemia treating medicine composition
CN
22.08.2007
A61K 38/57 Loading...
A61K 38/57
Loading...
200710004938.0
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
The present invention relates to the application of ulinastatin and/or alpha-1 thymulin in preparing medicine for preventing and treating pyemia and the medicine therewith. Ulinastatin and/or alpha-1 thymulin have obvious pyemia treating effect. The medicine is prepared into injection or freeze dried powder for injection.
48. 1931875 High purity ulinastatin and its prepn process and medicine composition
CN
21.03.2007
C07K 14/81 Loading...
C07K 14/81
Loading...
200610000601.8
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
C07K 14/81
Loading...
The present invention relates to high purity ulinastatin and its medicine composition and their preparation process. Specially, the high purity ulinastatin in 50,000 U/ml concentration has optical absorption value at 405 nm not exceeding 0.05 and human urea kininogenase content not exceeding 0.0003 PNAU. The present invention purifies ulinastatin product through adsorption with hydrophobic column, purification in hydrophilic column, combination with metalloprotein in metal chelating column and elution with buffering phosphate solution.
49. 1931362 Application of human urokinase-type peptidase in preparing medicine for treating diabetes combined cerebral infraction
CN
21.03.2007
A61K 38/49 Loading...
A61K 38/49
Loading...
200610127956.3
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 38/49
Loading...
The present invention relates to new medicinal use of human urokininogenase. Human urokininogenase is used in preparing medicine for preventing and treating diabetes combined cerebral infraction. Clinically, the dosage of human urokininogenase in intravenous injection is 1-2 kilounit each time and once or twice a day. Human urokininogenase has obvious curative effect on diabetes combined cerebral infraction.
50. WO/2006/094467 A BLOOD PURIFICATION METHOD AND SYSTEM BASED ON AFFINITY ABSORPTION
WO
14.09.2006
A61M 1/34 Loading...
A61M 1/34
Loading...
PCT/CN2006/000371
FU, Heliang
FU, Heliang
A61M 1/34
Loading...
A blood purification system includes a first absorption column with proteins as ligands and a second absorption column with immobilized metal ions as ligands, wherein the first absorption column and the second absorption column are connected in series. A blood purification method includes a step for purifying absorption, followed by a step for absorbing protein ligands which are absorbed but then desorbed in the previous step.
51. 1830495 Blood purification method and system based on affinity absorption
CN
13.09.2006
A61M 1/38 Loading...
A61M 1/38
Loading...
200510011414.5
Fu Heliang
Fu Heliang
A61M 1/38
Loading...
A method based on affinity adsorption for cleaning blood to treat hyperlipemia, arteriosclerosis, immunopathy, etc features that the raw blood flows through the first affinity adsorption column for removing the pathogenic factors and the second one for adsorbing the ligand dropped from the first column. Its system is also disclosed.
52. 1824301 Purified ustading and its preparation method and medicinal composition containing said ustading
CN
30.08.2006
A61K 38/57 Loading...
A61K 38/57
Loading...
200610000200.2
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 38/57
Loading...
A purified ulinastatin is prepared through adsorbing by hydrophobic column, separating by gel column, combining metalloprotein by metallic chelating column, and eluting with phosphate buffering liquid. A composite medicine containing the purified ulinastatin also disclosed.
53. 1751740 Medicinal composition for treating arthritis
CN
29.03.2006
A61K 38/57 Loading...
A61K 38/57
Loading...
200510090365.9
Tianpu Bio-Chemical Medicine Co., Ltd., Guangdong
Fu Heliang
A61K 38/57
Loading...
A composite medicine in the form of freeze-dried powder injection or liquid injection for treating osteoarthritis and rheumatoid arthritis is prepared from ulinastatin (a human Urinary trypsin inhibitor), sodium hyaluronate and optional mannitol, glycine and dextran.
54. 1706493 Application of human urokinase-type peptidase in preparing medicine for treating pulmonary hypertension
CN
14.12.2005
A61K 9/08 Loading...
A61K 9/08
Loading...
200410088439.0
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 9/08
Loading...
The present invention relates to the application of human urokinase-type peptidase in preparing medicine for treating pulmonary hypertension and the medicine composition prepared on the method. The human urokinase-type peptidase of the present invention has obvious treating effect on pulmonary hypertension, and the medicine composition is normally compounded into freeze powder for injection or injection liquid.
55. 1695735 Application of kininogenase of human urine in preparing medication for treating pyemia
CN
16.11.2005
A61K 38/49 Loading...
A61K 38/49
Loading...
200410088441.8
tianpu Biochemistry Pharmacy Co., Ltd., Guangdong
Fu Heliang
A61K 38/49
Loading...
An application of human prourokinase in preparing the composite medicine for preventing and treating pyemia, and the prepared composite medicine in the form of injection or freeze-dried powder injection are disclosed.
56. 1634575 Application of human urine kininogenase for preparing medicine to treat acute coronary syndromes
CN
06.07.2005
A61K 38/49 Loading...
A61K 38/49
Loading...
200410088440.3
Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/49
Loading...
The invention relates to the pharmaceutical use of human urinary kallikrein in the treatment of acute coronary artery disease and pharmaceutical composition prepared by the method. Human urinary kallikrein of the invention has an evident therapeutic function for the acute coronary artery disease. In general, it is used by preparing the pharmaceutical composition to freeze dried powder injection and injection liquid.
57. 1634576 Medicine composition for improving stability of human urine kininogenase
CN
06.07.2005
A61K 38/49 Loading...
A61K 38/49
Loading...
200410096060.4
Guangdong Tianpu Biochemical Pharmaceutical Co., Ltd.
Fu Heliang
A61K 38/49
Loading...
A pharmaceutical composition for improving biological activity stability of human urinary kallikrein is disclosed. The composition chooses one or combination of the following ingredients: mannitol, dextran intradex, hydrolyzed gelatin and sodium citrate to prepare liquid. In clinical practice, it is used for dissolving freeze dried human urinary kallikrein, then being dissolved to large volume liquid. It can delay evidently the decreasing of the human urinary kallikrein activity.
58. 1611503 Method for separating lycoramine from plant extract
CN
04.05.2005
C07D 491/06 Loading...
C07D 491/06
Loading...
200310102275.8
Tianpu Biochemical Pharmaceutical Co., Ltd. Guangdong
Fu Heliang
C07D 491/06
Loading...
The invention relates to a kind of effective constituent separation method in vegetation extract, especially the method of separating lycoramine from vegetation extract containing amaryllidaceae alkaloid. The industrial art is as follows: make vegetation extract containing amaryllidaceae alkaloid have pretreatment; adsorb and elute with cation exchange resin; track and detect the elution flowing composition; make the flowing composition in lycoramine have concentration and enrichment; after get virgin product of lycoramine free alkali, make it have recrystallization with organic solvent; finally, the lycoramine free alkali crystallization with about 99% purity can be acquired.
59. 1611504 Method for separating lycorine from plant extract
CN
04.05.2005
C07D 491/16 Loading...
C07D 491/16
Loading...
200310102276.2
Tianpu Biochemical Pharmaceutical Co., Ltd., Guangdong
Fu Heliang
C07D 491/16
Loading...
The invention relates to a kind of effective constituent separation method in vegetation extract, especially the method of separating lycorine from vegetation extract containing amaryllidaceae alkaloid. The industrial art is as follows: make vegetation extract containing amaryllidaceae alkaloid have pretreatment; adsorb and elute with cation exchange resin; track and detect the elution flowing composition; make the flowing composition in lycorine have concentration and enrichment; after get virgin product of lycorine free alkali, make it have recrystallization with organic solvent; finally, the lycorine free alkali crystallization with about 99% purity can be acquired.
60. 1611502 Method for separating galanthamine from plant extract
CN
04.05.2005
C07D 491/06 Loading...
C07D 491/06
Loading...
200310102274.3
Tianpu Biochemical Pharmaceutical Co., Ltd., Guangdong
Fu Heliang
C07D 491/06
Loading...
The invention relates to a kind of effective constituent separation method in vegetation extract, especially the method of separating galantamine from vegetation extract containing amaryllidaceae alkaloid. The industrial art is as follows: make vegetation extract containing amaryllidaceae alkaloid have pretreatment; adsorb and elute with cation exchange resin; track and detect the elution flowing composition; make the flowing composition in galantamine have concentration and enrichment; after get virgin product of galantamine free alkali, make it have recrystallization with organic solvent; finally, the galantamine free alkali crystallization with about 99% purity can be acquired.
61. 1583749 Process for extracting amarylid alkaloid from natural plant
CN
23.02.2005
C07D 491/04 Loading...
C07D 491/04
Loading...
03153992.0
Tianpu Biochemistry Medicine Co., Ltd., Guangdong Prov.
Fu Heliang
C07D 491/04
Loading...
The present invention relates to a process for extracting amaryllidaceae alkaloid from natural plants. Said process comprises exposing the natural plant to microwave irradiation in a microwave oven, using water or acidified water or organic solvent to extract, filtering, thereby the amaryllidaceae alkaloid containg solution is obtained, which can be used in subsequent procedures for separating and purifying active ingredients such as Galanthamine. The present process is an alternative for conventional acidified water leaching or organic solvent extraction, which is simple to operate while giving a higher yield, saving time, solvent and costs, thus is applicabe for industrial production.
62. 1449823 Use of ulinastatin in treating SARS and medicinal composition thereof
CN
22.10.2003
A61K 9/08 Loading...
A61K 9/08
Loading...
03125188.9
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61K 9/08
Loading...
The present invention relates to application of ulinastation for curing and preventing SARS and its medicine composition. Said invented ulinastatin has obvious action for curing and preventing SARS, specially for curing and preventing ALI or ARDS due to SARS. Generally, said invented ulinastatin can be used in the form of medicine composition, for example dried powder injection and/or liquid injection.
63. 1403156 Application of human urokininogenase in preparing medicine for preventing and treating cerebral infraction
CN
19.03.2003
A61P 9/10 Loading...
A61P 9/10
Loading...
02116783.4
Guangdong Tianpu Biochemical Medicine Co., Ltd.
Fu Heliang
A61P 9/10
Loading...
THe present invention discloses one new application of human urokininogenase in pharmaceutical engineering. Specially, human urokininogenase is used as active component in preparing injection for preventing and treating cerebral infraction.

